Ilyang Pharm (007570) — Capital Reinvestment Ratio
Ilyang Pharm (007570) has a Capital Reinvestment Ratio of 1.47x as of June 2025, meaning it reinvests 1% of its operating cash flow (₩2.26 Billion) in capital expenditures (₩3.32 Billion). See Ilyang Pharm balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Ilyang Pharm Capital Reinvestment Ratio (2003–2024)
This chart tracks Ilyang Pharm's Capital Reinvestment Ratio across 12 annual periods. Check 007570 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Ilyang Pharm (2003–2024)
Year-by-year Capital Reinvestment Ratio for Ilyang Pharm from 2003 to 2024. For live market cap and broader valuation context, see 007570 market cap.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 7.23x | ₩5.61 Billion | ₩40.62 Billion | ▲ +1391.3% |
| 2023 | 0.49x | ₩13.34 Billion | ₩6.47 Billion | ▲ +255.8% |
| 2022 | 0.14x | ₩29.94 Billion | ₩4.08 Billion | ▼ -29.2% |
| 2021 | 0.19x | ₩67.02 Billion | ₩12.91 Billion | ▲ +8.8% |
| 2020 | 0.18x | ₩57.48 Billion | ₩10.17 Billion | ▲ +194.7% |
| 2019 | 0.06x | ₩36.19 Billion | ₩2.17 Billion | ▼ -14.1% |
| 2018 | 0.07x | ₩22.12 Billion | ₩1.55 Billion | ▼ -44.5% |
| 2017 | 0.13x | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.0% |
| 2016 | 0.38x | ₩26.98 Billion | ₩10.31 Billion | ▼ -4.3% |
| 2015 | 0.40x | ₩40.27 Billion | ₩16.07 Billion | ▼ -46.5% |
| 2014 | 0.75x | ₩18.63 Billion | ₩13.89 Billion | ▲ +1710.6% |
| 2003 | 0.04x | ₩10.08 Billion | ₩415.11 Million | — |